/
Oncology
Hepatocellular Carcinoma
259
Pipeline Programs↗
430
Active Trials↗
135
Companies Involved↗
Hepatocellular Carcinoma is a highly competitive landscape with 259 programs across 135 companies. The most active players are Bayer, Shanghai Henlius Biotech, AstraZeneca. 54 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical72
Phase 139
Phase 294
Phase 354
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
181 of 226 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 226 classified programs, each share of the total. Modality classified for 96% of 259 pipeline programs.
Analysis
Trial Status
1,206
clinical trials
Completed356 · 30%
Unknown status267 · 22%
Recruiting238 · 20%
Not yet recruiting117 · 10%
Terminated105 · 9%
Active, not recruiting74 · 6%
Other49 · 4%
Clinical Trials
Trial Activity
1206 trials
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Lenvatinib, Radiotherapy, and Hepatic Arterial Infusion Chemotherapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07776080·35 enrolled
Page 1 of 81
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)